TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24853094

Group type: EXPERIMENTAL
Intervention: Ergocalciferol 20,000 IU/week
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Ergocalciferol 40,000 IU/week
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 22417930

Group type: EXPERIMENTAL
Intervention: ECT stimulus at 900 mA
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: ECT stimulus at 1150 mA
Number of subjects: 18
Study: 20008701

Group type: EXPERIMENTAL
Intervention: Bupropion SR
Number of subjects: 1346

Group type: EXPERIMENTAL
Intervention: Nicotine lozenge
Number of subjects: 1346

Group type: EXPERIMENTAL
Intervention: Nicotine patch
Number of subjects: 1346

Group type: EXPERIMENTAL
Intervention: Patch + lozenge
Number of subjects: 1346

Group type: EXPERIMENTAL
Intervention: Bupropion SR + lozenge
Number of subjects: 1346
Study: 16269248

Group type: EXPERIMENTAL
Intervention: EEG-fMRI
Number of subjects: 17

Group type: COMPARATOR
Intervention: EEG dipole source localisation
Number of subjects: 17

Group type: COMPARATOR
Intervention: Distributed source modelling
Number of subjects: 17
Study: 14564941

Group type: EXPERIMENTAL
Intervention: Daily foodlet containing multiple micronutrients
Number of subjects: 280

Group type: COMPARATOR
Intervention: Daily placebo foodlet containing no micronutrients
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Weekly foodlet containing multiple micronutrients (twice the dose of the daily foodlet) and placebo foodlets on other days
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Daily foodlet containing only 10 mg of elemental iron
Number of subjects: 280
Study: 10926646

Group type: EXPERIMENTAL
Intervention: Water immersion (WI) for 3 hours
Number of subjects: 19

Group type: COMPARATOR
Intervention: Seated nonimmersed for 5.5 hours (control)
Number of subjects: 19
Study: 8880795

Group type: EXPERIMENTAL
Intervention: DDD pacing mode
Number of subjects: 18

Group type: COMPARATOR
Intervention: VVIR pacing mode
Number of subjects: 18
Study: 1357152

Group type: EXPERIMENTAL
Intervention: Low-dose oral interferon-alpha (50 U)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: High-dose oral interferon-alpha (100 U)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study: 4005103

Group type: EXPERIMENTAL
Intervention: Ciclazindol hydrochloride (50 mg twice daily)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Desipramine hydrochloride (50 mg twice daily)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Lactose placebo (twice daily)
Number of subjects: 29
Study: 31144979

Group type: EXPERIMENTAL
Intervention: Diet with 0.6 g protein/kg body weight
Number of subjects: 41

Group type: COMPARATOR
Intervention: Diet with 1 g protein/kg body weight
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Overall participants
Number of subjects: 41
Study: 29566934

Group type: EXPERIMENTAL
Intervention: Once-daily 7.5mg tolvaptan
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Twice-daily 3.75mg tolvaptan
Number of subjects: 31
Study: 26272586

Group type: EXPERIMENTAL
Intervention: Low-fat meal (500 mg ceritinib)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: High-fat meal (500 mg ceritinib)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Light snack (750 mg ceritinib)
Number of subjects: 2
Study: 24819761

Group type: EXPERIMENTAL
Intervention: 10% LF ointment
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 20% LF ointment
Number of subjects: 30

Group type: COMPARATOR
Intervention: Oral bovine LF 100 mg
Number of subjects: 30
Study: 22476844

Group type: EXPERIMENTAL
Intervention: Preoperative thromboprophylaxis with dalteparin (starting 12 hours before surgery)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Postoperative thromboprophylaxis with dalteparin (starting 6 hours after surgery)
Number of subjects: 80
Study: 20451185

Group type: EXPERIMENTAL
Intervention: 0.2 mL of air pushed into the catheter after embryo transfer
Number of subjects: 55

Group type: COMPARATOR
Intervention: Standard embryo transfer technique (without air)
Number of subjects: 55
Study: 18408261

Group type: EXPERIMENTAL
Intervention: Breath ammonia measurement using a QCM-NH3 sensor
Number of subjects: 0
Study: 15765988

Group type: EXPERIMENTAL
Intervention: 11 mg dose of bupivacaine with 20 microg of fentanyl
Number of subjects: 42

Group type: COMPARATOR
Intervention: 6.5 mg dose of bupivacaine with 20 microg of fentanyl
Number of subjects: 42
Study: 11801426

Group type: EXPERIMENTAL
Intervention: Endoscopic carpal tunnel release (ECTR)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Open carpal tunnel release (OCTR)
Number of subjects: 66
Study: 15374060

Group type: EXPERIMENTAL
Intervention: Carvedilol (6.25 mg twice daily for the first week, increased to 12.5 mg during weeks 2-4, and to 25 mg from weeks 5-12)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 7579469

Group type: EXPERIMENTAL
Intervention: Filtered blood products
Number of subjects: 502

Group type: COMPARATOR
Intervention: CMV-seronegative blood products
Number of subjects: 502
Study: 1668100

Group type: EXPERIMENTAL
Intervention: Evening primrose oil (Efamol) rich in linoleic and gamma-linolenic acids for 8 months
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 7139977

Group type: EXPERIMENTAL
Intervention: Intravenous labetalol
Number of subjects: 12

Group type: COMPARATOR
Intervention: Intravenous dihydralazine
Number of subjects: 12
Study: 30753625

Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplements (LNSs) during pregnancy and postpartum plus LNSs for infants from 6 to 18 months
Number of subjects: 1320

Group type: COMPARATOR
Intervention: Non-LNS group (iron and folic acid during pregnancy and 200 mg Ca for 6 months postpartum; multiple micronutrients during pregnancy and postpartum)
Number of subjects: 1320
Study: 27016157

Group type: EXPERIMENTAL
Intervention: Definitive abutment placed at the time of implant placement
Number of subjects: 40

Group type: COMPARATOR
Intervention: Definitive abutment placed 6-12 weeks later (control group)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups (control and test)
Number of subjects: 40
Study: 26174581

Group type: EXPERIMENTAL
Intervention: Low glycaemic index milk (GI = 23)
Number of subjects: 56

Group type: COMPARATOR
Intervention: High glycaemic index milk (GI = 65)
Number of subjects: 56
Study: 23907700

Group type: EXPERIMENTAL
Intervention: Simeprevir (75 or 150 mg QD) with Pegylated interferon and ribavirin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo with Pegylated interferon and ribavirin
Number of subjects: 0
Study: 21409538

Group type: EXPERIMENTAL
Intervention: Worksheet provided
Number of subjects: 241

Group type: COMPARATOR
Intervention: No worksheet provided (Control)
Number of subjects: 241
Study: 18987053

Group type: EXPERIMENTAL
Intervention: morphine 1 mg ml(‐1) plus dexmedetomidine 5 microg ml(‐1) (Group D)
Number of subjects: 100

Group type: COMPARATOR
Intervention: morphine 1 mg ml(‐1) alone (Group M)
Number of subjects: 100
Study: 17606247

Group type: EXPERIMENTAL
Intervention: Social support from family and friends for healthy eating
Number of subjects: 1942

Group type: EXPERIMENTAL
Intervention: Support from friends
Number of subjects: 1942
Study: 12653820

Group type: EXPERIMENTAL
Intervention: HELP clinic intervention
Number of subjects: 470

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 470
Study: 10506237

Group type: EXPERIMENTAL
Intervention: Feedback group (physicians received written feedback about compliance scores)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Feedback and incentive group (physicians received feedback and a financial bonus when compliance criteria were met)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 8616760

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 184
Study: 1751561

Group type: EXPERIMENTAL
Intervention: Intravenous digital subtraction angiography (DSA)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Intra-arterial digital subtraction angiography (DSA)
Number of subjects: 36
Study: 7332740

Group type: EXPERIMENTAL
Intervention: SC8109
Number of subjects: 6

Group type: COMPARATOR
Intervention: spironolactone
Number of subjects: 6
Study: 31250182

Group type: EXPERIMENTAL
Intervention: Rehabilitation program (8-week, bi-weekly education and exercise program)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Rehabilitation program
Number of subjects: 188
Study: 30406378

Group type: EXPERIMENTAL
Intervention: mHealth intervention (nurse's online guidance through a mobile medical App and regular offline clinical treatment)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: mHealth intervention
Number of subjects: 124
Study: 28292319

Group type: EXPERIMENTAL
Intervention: KLH
Number of subjects: 553

Group type: COMPARATOR
Intervention: MM
Number of subjects: 553
Study: 25061029

Group type: EXPERIMENTAL
Intervention: Adapted physical activity (APA) intervention, consisting of an exercise program with ten sessions, two times a week for one hour each.
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (CG) with observation only, no intervention.
Number of subjects: 37
Study: 22708917

Group type: EXPERIMENTAL
Intervention: Flapless implants
Number of subjects: 20

Group type: COMPARATOR
Intervention: Flapped implants
Number of subjects: 20
Study: 22093849

Group type: EXPERIMENTAL
Intervention: Methylprednisolone 1000 mg/d for 3 days plus bronchoalveolar lavage
Number of subjects: 21

Group type: COMPARATOR
Intervention: Methylprednisolone 1000 mg/d for 3 days
Number of subjects: 21
Study: 18661135

Group type: EXPERIMENTAL
Intervention: Irradiated parotid glands
Number of subjects: 19

Group type: COMPARATOR
Intervention: Non-irradiated parotid glands
Number of subjects: 19
Study: 16464717

Group type: EXPERIMENTAL
Intervention: SPECT ERNA
Number of subjects: 27

Group type: COMPARATOR
Intervention: EBCT
Number of subjects: 27
Study: 14996518

Group type: EXPERIMENTAL
Intervention: Glimepiride (initially 2 mg once daily, increased by 1 mg every 2 weeks until FPG <6.7 mmol/L, maintained for 24 weeks)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Glimepiride
Number of subjects: 14

Group type: COMPARATOR
Intervention: Oral glucose tolerance tests (OGTTs) conducted in the control group
Number of subjects: 14
Study: 10364997

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine
Number of subjects: 11
Study: 7863712

Group type: EXPERIMENTAL
Intervention: ATP mode A
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: ATP mode B
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: ATP mode C
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: ATP mode D
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: ATP mode E
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Pre-discharge EP
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Post-op ATP
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Primary ICD shocks
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: ATP
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Overall follow-up
Number of subjects: 82
Study: 1911428

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: No chemotherapy (non-responders)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Patients with respiratory failure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Total testosterone concentrations
Number of subjects: 0
Study: 7240597

Group type: EXPERIMENTAL
Intervention: Potassium metabisulfite (K2S2O5) oral challenges
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study: 30600961

Group type: EXPERIMENTAL
Intervention: Anterolateral thigh flap transfer
Number of subjects: 80

Group type: COMPARATOR
Intervention: Forearm flap transfer
Number of subjects: 80
Study: 29099947

Group type: EXPERIMENTAL
Intervention: rhPTH(1‐84) (n = 83)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo (n = 39)
Number of subjects: 122
Study: 27183138

Group type: EXPERIMENTAL
Intervention: iohexol
Number of subjects: 102

Group type: COMPARATOR
Intervention: iodixanol
Number of subjects: 102
Study: 24668102

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Number of subjects: 136

Group type: COMPARATOR
Intervention: Endoscopic surveillance
Number of subjects: 136
Study: 22776430

Group type: EXPERIMENTAL
Intervention: Sirolimus (n = 57)
Number of subjects: 116

Group type: COMPARATOR
Intervention: CNI (n = 59)
Number of subjects: 116
Study: 20214065

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with oral administration of Propranolol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oral administration of Propranolol only
Number of subjects: 60
Study: 16580027

Group type: EXPERIMENTAL
Intervention: Vision alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Touch alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Touch and vision together
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multimodal (vision and touch)
Number of subjects: 0
Study: 16239762

Group type: EXPERIMENTAL
Intervention: Amantadine 200 mg twice daily
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 11851956

Group type: EXPERIMENTAL
Intervention: Mass drug administration (MDA) of diethylcarbamazine (DEC) plus ivermectin (IVR)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Mass drug administration (MDA) of diethylcarbamazine (DEC) plus ivermectin (IVR) with vector control
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Vector control
Number of subjects: 7
Study: 10190770

Group type: EXPERIMENTAL
Intervention: 1:1 ratio of concentric to eccentric contractions
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: 1:2 ratio of concentric to eccentric contractions
Number of subjects: 2
Study: 7635603

Group type: EXPERIMENTAL
Intervention: Nutrition supplementation during early childhood
Number of subjects: 460
Study: 31571392

Group type: EXPERIMENTAL
Intervention: Limited sampling strategy (LSS) to predict tacrolimus AUC0-12h
Number of subjects: 56

Group type: COMPARATOR
Intervention: Prograf® or non-innovator tacrolimus formulations
Number of subjects: 56
Study: 28398692

Group type: EXPERIMENTAL
Intervention: 7 days intravenous antibiotics
Number of subjects: 132

Group type: COMPARATOR
Intervention: 10 days intravenous antibiotics
Number of subjects: 132
Study: 25567659

Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control
Number of subjects: 150
Study: 23296434

Group type: EXPERIMENTAL
Intervention: Standardized measures of infant neurodevelopment
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Age at baseline
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Parent-reported functional abilities and hemoglobin concentration
Number of subjects: 193
Study: 22111658

Group type: EXPERIMENTAL
Intervention: Alfentanil 7.5 μg/kg
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl)
Number of subjects: 90
Study: 19393046

Group type: EXPERIMENTAL
Intervention: Patient education intervention (DVD and written workbook)
Number of subjects: 1206

Group type: EXPERIMENTAL
Intervention: Patient education intervention (DVD and written workbook) + follow up education training visits by a health professional
Number of subjects: 1206

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1206
Study: 17644072

Group type: EXPERIMENTAL
Intervention: Atomoxetine (60 mg)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 14722176

Group type: EXPERIMENTAL
Intervention: Fentanyl 0.5 micro g kg(‐1)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Fentanyl 1 micro g kg(‐1)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Fentanyl 2 micro g kg(‐1)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Fentanyl (0.5 to 1 micro g kg(‐1))
Number of subjects: 64
Study: 11712623

Group type: EXPERIMENTAL
Intervention: Netamiftide (18 mg/patient per day) for 10 days
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Netamiftide (18 mg/patient per day) for 5 days followed by 5 days of placebo
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo for 10 days
Number of subjects: 55
Study: 9042130

Group type: EXPERIMENTAL
Intervention: Pill form of cholestyramine (8 gm/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Powder form of cholestyramine (8 gm/day)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both forms of cholestyramine
Number of subjects: 40
Study: 8162917

Group type: EXPERIMENTAL
Intervention: Low impact dance
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High impact dance with arm work
Number of subjects: 10

Group type: COMPARATOR
Intervention: Dance (various styles)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Stepping (traditional step test)
Number of subjects: 10
Study: 2835964

Group type: COMPARATOR
Intervention: E + P (Enalapril + Placebo)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: E + H 12.5 (Enalapril + Hydrochlorothiazide 12.5 mg/day)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: E + H 25 (Enalapril + Hydrochlorothiazide 25 mg/day)
Number of subjects: 200
Study: 31913422

Group type: EXPERIMENTAL
Intervention: Decompressing stoma (DS)
Number of subjects: 3153

Group type: COMPARATOR
Intervention: Self‐expandable metal stent (SEMS)
Number of subjects: 3153
Study: 30067928

Group type: EXPERIMENTAL
Intervention: 4 months of rifampin
Number of subjects: 844

Group type: COMPARATOR
Intervention: 9 months of isoniazid
Number of subjects: 844
Study: 26967547

Group type: EXPERIMENTAL
Intervention: 15-minute patterned electrical neuromuscular stimulation (PENS) treatment
Number of subjects: 22

Group type: COMPARATOR
Intervention: 15-minute 1-mA subsensory (sham) treatment
Number of subjects: 22
Study: 25645567

Group type: EXPERIMENTAL
Intervention: Exenatide once weekly
Number of subjects: 0
Study: 23870798

Group type: EXPERIMENTAL
Intervention: VPA + memantine (5 mg/day)
Number of subjects: 135

Group type: COMPARATOR
Intervention: VPA + placebo
Number of subjects: 135
Study: 20103449

Group type: EXPERIMENTAL
Intervention: Levonorgestrel Intrauterine System
Number of subjects: 23

Group type: COMPARATOR
Intervention: Copper T 380A
Number of subjects: 23
Study: 18855244

Group type: EXPERIMENTAL
Intervention: Intranasal cocaine
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Aripiprazole (15 mg/day)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 15673850

Group type: EXPERIMENTAL
Intervention: Gastric decompression (n = 52)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group (n = 52)
Number of subjects: 104
Study: 12924677

Group type: EXPERIMENTAL
Intervention: Combination (multimodal) treatment
Number of subjects: 579

Group type: COMPARATOR
Intervention: Medication management
Number of subjects: 579

Group type: EXPERIMENTAL
Intervention: Behavioral treatment
Number of subjects: 579

Group type: EXPERIMENTAL
Intervention: Community care
Number of subjects: 579
Study: 11110017

Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8763370

Group type: EXPERIMENTAL
Intervention: Gentisone HC
Number of subjects: 161

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 161
Study: 1724592

Group type: EXPERIMENTAL
Intervention: loratadine 10 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study: 6626112

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 558

Group type: EXPERIMENTAL
Intervention: Behaviour Therapy
Number of subjects: 558

Group type: COMPARATOR
Intervention: Placebo Medication
Number of subjects: 558

Group type: COMPARATOR
Intervention: Waiting-list Control
Number of subjects: 558
Study: 31241872

Group type: EXPERIMENTAL
Intervention: Integration of PHCCs with MOH hospitals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Improvement in registration counters’ load
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cleanliness of centers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Satisfaction with staff’s behavior
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ease in referral
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dental facilities
Number of subjects: 0
Study: 29968686

Group type: EXPERIMENTAL
Intervention: Laughter therapy program (12 sessions for 6 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no laughter therapy)
Number of subjects: 60
Study: 26489482

Group type: EXPERIMENTAL
Intervention: Protocolized sedation plus daily sedation interruption
Number of subjects: 430

Group type: COMPARATOR
Intervention: Protocolized sedation
Number of subjects: 430
Study: 24517298

Group type: EXPERIMENTAL
Intervention: Community-based palliative care
Number of subjects: 8
Study: 22953754

Group type: EXPERIMENTAL
Intervention: Online care management
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Telephone-based care management
Number of subjects: 151

Group type: COMPARATOR
Intervention: Web training
Number of subjects: 151
Study: 20231251

Group type: EXPERIMENTAL
Intervention: BCG vaccination
Number of subjects: 2871

Group type: COMPARATOR
Intervention: No vaccination (control)
Number of subjects: 2871
Study: 17435399

Group type: EXPERIMENTAL
Intervention: Back-pain-reducing program
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 52
Study: 15565494

Group type: EXPERIMENTAL
Intervention: S-L-tryptophan
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: S-free tryptophan
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: S-CAAs
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: S-cortisol
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: CSF-cortisol
Number of subjects: 37

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 37
Study: 11813997

Group type: EXPERIMENTAL
Intervention: Intensive rehabilitation (4 hours per day)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Intensive rehabilitation (2 hours per day)
Number of subjects: 36
Study: 9726390

Group type: EXPERIMENTAL
Intervention: Cisapride 10 mg q.d.s.
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 8306050

Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone (500 micrograms four times daily) for 1 month
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo for 1 month
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone
Number of subjects: 19